Pliant Therapeutics, Inc. (PLRX) |
|
23.68 0.68 (2.96%)
|
06-06 15:11 |
|
Open: |
23.06 |
Pre. Close: |
23 |
|
High:
|
23.8 |
Low:
|
22.81 |
|
Volume:
|
345,712 |
Market Cap:
|
1,401(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:50:34 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 28.32 One year: 33.08 |
| Support: |
Support1: 22.03 Support2: 20.65 |
| Resistance: |
Resistance1: 24.25 Resistance2: 28.32 |
| Pivot: |
21.92 |
| Moving Average: |
MA(5): 22.44 MA(20): 22.07
MA(100): 27.33 MA(250): 22.11 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 84 %D(3): 65.7 |
| RSI: |
RSI(14): 54.1 |
| 52-week: |
High: 36.63 Low: 6.36 |
| Average Vol(K): |
3-Month: 724 (K) 10-Days: 436 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PLRX ] has closed Bollinger Bands are 65.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
23.08 - 23.16 |
23.16 - 23.24 |
|
Low:
|
21.74 - 21.84 |
21.84 - 21.94 |
|
Close:
|
22.83 - 22.98 |
22.98 - 23.11 |
|
Company Description |
|
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. |
Headline News |
Tue, 06 Jun 2023
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by ... - MarketBeat
Mon, 05 Jun 2023
Over 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks - Yahoo Finance
Wed, 24 May 2023
Pliant Therapeutics Inc. (PLRX) Presents Data from Bexotegrast ... - StreetInsider.com
Thu, 18 May 2023
3 Best Stocks to Buy Now, 5/18/2023, According to Top Analysts - Nasdaq
Thu, 18 May 2023
Canaccord Genuity Initiates Coverage of Pliant Therapeutics (PLRX ... - Nasdaq
Thu, 11 May 2023
Oppenheimer Maintains Pliant Therapeutics (PLRX) Outperform ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
59 (M) |
|
% Held by Insiders
|
4.516e+007 (%) |
|
% Held by Institutions
|
6.6 (%) |
|
Shares Short
|
3,850 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3926e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
444.3 |
|
Return on Equity (ttm)
|
-22.2 |
|
Qtrly Rev. Growth
|
9.77e+006 |
|
Gross Profit (p.s.)
|
4.78 |
|
Sales Per Share
|
-26.16 |
|
EBITDA (p.s.)
|
7.02174e+006 |
|
Qtrly Earnings Growth
|
-2.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-104 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.91 |
|
Price to Cash Flow
|
3.42 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
6.16e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
